Small Molecule

Displaying 1 - 6 of 6


Targeted photodynamic therapy for S. aureus infections

Vanderbilt researchers have developed a combination photodynamic therapy (PDT) for targeting MRSA infections in skin that is not only effective but also HIGHLY SPECIFIC and LESS SUSCEPTIBLE TO RESISTANCE, adding a much needed therapy to our quickly depleting arsenal against this pathogen.


Licensing Contact

Cameron Sargent

615.322.5907

Targeted light-based therapy for acne

Vanderbilt researchers have developed a photodynamic therapy (PDT) for effectively and specifically treating acne, the most common skin condition.


Licensing Contact

Cameron Sargent

615.322.5907
Therapeutics
Small Molecule

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

Small Molecule-GIRK Potassium Channel Modulators That Are Anxiolytic Therapeutics

The G-protein activated, inward-rectifying potassium (K+) channels, "GIRKs", are a family of ion channels that has been the focus of intense research interest for nearly two decades. GIRK has been shown to play important roles in the pathophysiology of diseases such as anxiety, epilepsy, Down's syndrome, pain perception and drug addiction. Here scientists at Vanderbilt developed the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810) and demonstrated that ML297 is active in animal models of epilepsy. While the group is using ML297 to continue to explore the therapeutic benefits of GIRK modulation, they are continuing to develop more selective and druggable GIRK inhibitors from different scaffolds.


Licensing Contact

Cameron Sargent

615.322.5907
Therapeutics
Analgesic
Small Molecule

Metabolic Labeling Reagents for Chondroitin Sulfate

Dr. Patrick Page-McCaw has developed synthetic analogs of N-acetylgalactosamine, finally enabling researchers to track the biosynthesis of chondroitin sulfate along with other glycans. These stunning images demonstrate incorporation of these metabolic labeling reagents to track neurodevelopmental processes in a zebrafish model system. Notably, the metabolic label can be detected post vivo using a standard ""click"" chemistry reaction. Further, Dr. Page-McCaw has optimized a background reduction strategy to complement this technology by improving the signal-to-noise ratio.


Licensing Contact

Mike Villalobos

615.322.6751
Research Tools
Small Molecule
Imaging